BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33901770)

  • 21. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors.
    Pan L; Zheng Q; Chen Y; Yang R; Yang Y; Li Z; Meng X
    Eur J Med Chem; 2018 Sep; 157():423-436. PubMed ID: 30103191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.
    Wu Y; Duan Q; Zou Y; Zhu Q; Xu Y
    Bioorg Med Chem Lett; 2021 Nov; 52():128373. PubMed ID: 34560264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
    Cui G; Lai F; Wang X; Chen X; Xu B
    Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
    Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
    Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
    Weng T; Qiu X; Wang J; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory effects of flavonoids isolated from
    Kwon M; Ko SK; Jang M; Kim GH; Ryoo IJ; Son S; Ryu HW; Oh SR; Lee WK; Kim BY; Jang JH; Ahn JS
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1481-1488. PubMed ID: 31423846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.
    He X; He G; Chu Z; Wu H; Wang J; Ge Y; Shen H; Zhang S; Shan J; Peng K; Wei Z; Zou Y; Xu Y; Zhu Q
    J Med Chem; 2021 Dec; 64(24):17950-17968. PubMed ID: 34854662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
    Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
    Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
    Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
    Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
    Steeneck C; Kinzel O; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Czekańska M; Hoffmann T
    Bioorg Med Chem Lett; 2021 Feb; 33():127744. PubMed ID: 33333163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of IDO1 and DNA dual targeting antitumor agents.
    Fang K; Wu S; Dong G; Wu Y; Chen S; Liu J; Wang W; Sheng C
    Org Biomol Chem; 2017 Dec; 15(47):9992-9995. PubMed ID: 29177308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening.
    Zhou Y; Peng J; Li P; Du H; Li Y; Li Y; Zhang L; Sun W; Liu X; Zuo Z
    Comput Biol Chem; 2019 Feb; 78():306-316. PubMed ID: 30616156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
    Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X
    Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice.
    Zhang R; Wang Y; Liu D; Luo Q; Du P; Zhang H; Wu W
    Front Pharmacol; 2022; 13():870848. PubMed ID: 35571116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B.
    Shiokawa Z; Kashiwabara E; Yoshidome D; Fukase K; Inuki S; Fujimoto Y
    ChemMedChem; 2016 Dec; 11(24):2682-2689. PubMed ID: 27863031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
    Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
    Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.
    Zhou J; Yu LZ; Fan YL; Guo CH; Lv XM; Zhou ZY; Huang HD; Miao DD; Zhang SP; Li XY; Zhao PP; Liu XP; Hu WH; Zhang C
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114860. PubMed ID: 36370550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.
    Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.